Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Randomised, Double-Blind, Placebo Controlled Study, Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy of Single and Multiple Intravenous Doses of ALX-0061 in Patients With RA

NCT01284569 is registered in ClinicalTrials.gov with Ablynx, a Sanofi company as lead sponsor.

NCT NCT01284569
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01284569 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Randomised, Double-Blind, Placebo Controlled Study, Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy of Single and Multiple Intravenous Doses of ALX-0061 in Patients With RA
Lead sponsor
Ablynx, a Sanofi company
Phase
Phase 1/2
Overall status
Completed
Start date
March 31, 2011
Completion date
September 30, 2012
Enrollment
65 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis